Humming in Q1 I’ve had a rough year, but Revive (RVV.C) sure hasn’t. With a portfolio based around psychedelics, cannabis, and diseases – this company has made 3…
Search Results for: RVV.C – Page 5
Revive Therapeutics (RVV.C) advanced the December 21 deal with Newscope Capital (PHRM.C) past a binding LOI and into a purchase agreement to acquire psilocybin intellectual property from Newscope’s subsidiary,…
Revive Therapeutics (RVV.C) and 17 other companies in the United States and Canada joined the first psychedelic exchange-traded fund, managed by Horizons ETF management today, according to a press…
Revive Therapeutics (RVV.C) entered into a sponsored research agreement and license agreement with North Carolina State University (NC State), developing a biosynthetic version of psilocybin today, according to a…
On December 20, 2020, Revive Therapeutics (RVV.C) inked a non-binding letter of intent for the full rights to PharmaTher’s psilocybin intellectual property, according to a press release. PharmaTher is…
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space….
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”….
One of the unfortunate downsides of living in the 21st century is the fact that most of us will have to deal with cancer in our lifetimes. The numbers…
Revive Therapeutics (RVV.C) is bouncing from a very significant support zone. Don’t believe me? Look at how price reacted in the past. This is the fourth time price has…
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research…